Genoway SA
PAR:ALGEN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.36
4.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Genoway SA
Genoway SA
Current Portion of Long-Term Debt
Genoway SA
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genoway SA
PAR:ALGEN
|
Current Portion of Long-Term Debt
€1.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Current Portion of Long-Term Debt
€22.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Current Portion of Long-Term Debt
€8.9m
|
CAGR 3-Years
57%
|
CAGR 5-Years
39%
|
CAGR 10-Years
36%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Current Portion of Long-Term Debt
€8m
|
CAGR 3-Years
41%
|
CAGR 5-Years
13%
|
CAGR 10-Years
45%
|
|
|
Inventiva SA
PAR:IVA
|
Current Portion of Long-Term Debt
€5.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Current Portion of Long-Term Debt
€15m
|
CAGR 3-Years
52%
|
CAGR 5-Years
14%
|
CAGR 10-Years
36%
|
|
Genoway SA
Glance View
genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
See Also
What is Genoway SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.7m
EUR
Based on the financial report for Jun 30, 2024, Genoway SA's Current Portion of Long-Term Debt amounts to 1.7m EUR.
What is Genoway SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
18%
Over the last year, the Current Portion of Long-Term Debt growth was -18%. The average annual Current Portion of Long-Term Debt growth rates for Genoway SA have been 6% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
